CINECA IRIS Institutional Research Information System

GAMBALE, CARLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.624
AS - Asia 1.459
EU - Europa 1.185
SA - Sud America 254
Continente sconosciuto - Info sul continente non disponibili 114
AF - Africa 110
Totale 5.746
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.547
SG - Singapore 503
IT - Italia 440
CN - Cina 396
DE - Germania 223
HK - Hong Kong 201
BR - Brasile 199
VN - Vietnam 138
SE - Svezia 105
AT - Austria 82
FR - Francia 62
GB - Regno Unito 62
FI - Finlandia 50
CA - Canada 45
CI - Costa d'Avorio 43
BG - Bulgaria 39
JP - Giappone 38
IN - India 37
TR - Turchia 28
RU - Federazione Russa 24
KR - Corea 22
SN - Senegal 22
AR - Argentina 21
BD - Bangladesh 20
PL - Polonia 18
NL - Olanda 17
MX - Messico 16
MA - Marocco 15
EE - Estonia 14
ZA - Sudafrica 13
PK - Pakistan 9
SA - Arabia Saudita 9
UA - Ucraina 9
ES - Italia 8
UZ - Uzbekistan 8
EC - Ecuador 7
IQ - Iraq 7
VE - Venezuela 7
CZ - Repubblica Ceca 6
CL - Cile 5
IR - Iran 5
LT - Lituania 5
MG - Madagascar 5
PE - Perù 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CO - Colombia 4
JM - Giamaica 4
NP - Nepal 4
CY - Cipro 3
GR - Grecia 3
HU - Ungheria 3
ID - Indonesia 3
JO - Giordania 3
TH - Thailandia 3
UY - Uruguay 3
BE - Belgio 2
BO - Bolivia 2
GT - Guatemala 2
IE - Irlanda 2
IL - Israele 2
KE - Kenya 2
KZ - Kazakistan 2
LV - Lettonia 2
MC - Monaco 2
MY - Malesia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
SV - El Salvador 2
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
GD - Grenada 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LB - Libano 1
MT - Malta 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TG - Togo 1
TT - Trinidad e Tobago 1
ZM - Zambia 1
Totale 5.633
Salva come PNG Salva come JPEG
Città #
Dallas 392
Ashburn 316
Singapore 305
San Jose 283
Hong Kong 192
Santa Clara 152
Chandler 126
Milan 120
New York 82
Shanghai 78
Beijing 75
Vienna 75
Munich 71
Los Angeles 68
Pisa 52
Fairfield 47
Abidjan 43
Boardman 41
Sofia 39
Ho Chi Minh City 35
Tokyo 35
Hefei 34
Rome 31
Seattle 31
Hanoi 30
Council Bluffs 28
Helsinki 27
Wilmington 27
Houston 26
Frankfurt am Main 24
Cambridge 23
Florence 23
Woodbridge 23
Dakar 22
Princeton 22
Atlanta 21
Lauterbourg 21
Seoul 21
Buffalo 20
Redondo Beach 20
São Paulo 20
Lawrence 19
Turku 18
Denver 14
London 14
Orem 14
Montreal 13
Brooklyn 12
Columbus 12
Belo Horizonte 11
Casablanca 11
Cascina 11
Fuzhou 11
Istanbul 11
Lucca 11
Dong Ket 10
Medford 10
Mexico City 10
Serra 10
Warsaw 10
Boulder 9
Johannesburg 9
Poplar 9
Ann Arbor 8
Bologna 8
Chicago 8
Memphis 8
San Diego 8
Tashkent 8
Toronto 8
Vancouver 8
Düsseldorf 7
Haiphong 7
Livorno 7
Ogden 7
Quanzhou 7
Stockholm 7
Washington 7
Amsterdam 6
Brasília 6
Nuremberg 6
Ottawa 6
Vicopisano 6
Antananarivo 5
Baghdad 5
Bremen 5
Da Nang 5
Guayaquil 5
Jeddah 5
Lima 5
Modena 5
Mumbai 5
Nanjing 5
Rio de Janeiro 5
Samsun 5
Turin 5
Xiamen 5
Zhengzhou 5
Baku 4
Baltimore 4
Totale 3.606
Salva come PNG Salva come JPEG
Nome #
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 243
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 214
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 190
18F-DOPA-PET/CT role in medullary thyroid cancer patients with biochemical incomplete response 182
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 181
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 179
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 177
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 167
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 164
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 164
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 158
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 157
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 156
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 154
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 149
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 147
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 139
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 136
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 134
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 131
Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience 129
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 129
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 128
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 128
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 120
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 118
Erectile dysfunction in patients treated with selpercatinib for RET altered thyroid cancer 117
Hypothesizing a role of ret hyperactivation on weight control in patients with type 2A multiple endocrine neoplasia (MEN2A) 114
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 113
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 113
Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review 107
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 99
Ultrasound features and risk stratification system in NIFT-P and other follicular-patterned thyroid tumors 98
BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review 95
Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib 92
Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules 87
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine 79
Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients 76
Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib 65
Timing and Ideal Patient for an Appropriate Search for Somatic RET Mutation in Medullary Thyroid Cancer 60
Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease 44
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers 30
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment 23
Comparison of pre-operative calcitonin, FNAC, and ultrasound risk stratification systems in patients with medullary thyroid carcinoma 23
Impairment in the hypothalamic-pituitary-gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib 4
Totale 5.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022166 0 4 5 2 31 28 5 8 9 7 13 54
2022/2023497 32 56 51 36 54 54 20 44 109 5 29 7
2023/2024468 42 56 70 39 62 76 21 7 13 9 30 43
2024/20251.407 26 43 28 82 148 126 129 65 135 161 160 304
2025/20262.377 167 346 274 233 236 137 315 82 133 222 99 133
2026/2027375 79 296 0 0 0 0 0 0 0 0 0 0
Totale 5.746